Published in J Urol on July 16, 2007
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol (2009) 1.92
Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators. J Urol (2010) 1.46
Inflammation and benign prostatic hyperplasia. Urol Clin North Am (2008) 1.44
Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol Cell (2016) 1.40
The role of an abnormal prostate-specific antigen level and an abnormal digital rectal examination in the diagnosis of prostate cancer: A cross-sectional study in Qatar. Arab J Urol (2013) 1.38
Role of inflammation in benign prostatic hyperplasia. Rev Urol (2011) 1.14
Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep (2008) 1.02
Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 1.02
Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation. J Biol Chem (2012) 0.99
Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology (2008) 0.97
Benign prostatic hyperplasia: from bench to clinic. Korean J Urol (2012) 0.96
Pain, catastrophizing, and depression in chronic prostatitis/chronic pelvic pain syndrome. Int Neurourol J (2013) 0.91
The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol (2012) 0.86
Depression, anxiety, stress perception, and coping strategies in korean military patients with chronic prostatitis/chronic pelvic pain syndrome. Korean J Urol (2012) 0.85
Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One (2014) 0.85
Development and validation of an animal model of prostate inflammation-induced chronic pelvic pain: evaluating from inflammation of the prostate to pain behavioral modifications. PLoS One (2014) 0.81
Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol (2016) 0.80
Action Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia. Evid Based Complement Alternat Med (2013) 0.80
Interleukin-driven insulin-like growth factor promotes prostatic inflammatory hyperplasia. J Pharmacol Exp Ther (2014) 0.79
Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis. Am J Pathol (2014) 0.79
Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study. Prostate Cancer Prostatic Dis (2016) 0.78
The relationship between histological prostatitis and lower urinary tract symptoms and sexual function. Int Braz J Urol (2016) 0.77
Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate. Am J Physiol Renal Physiol (2015) 0.77
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
Prostate cancer incidence in men with self-reported prostatitis after 15 years of follow-up. Oncol Lett (2016) 0.75
The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens. Prostate Cancer Prostatic Dis (2017) 0.75
Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget (2017) 0.75
Relation between histological prostatitis and lower urinary tract symptoms and erectile function. Prostate Int (2017) 0.75
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol (2007) 2.84
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol (2009) 2.30
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol (2004) 2.23
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology (2010) 2.19
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 2.01
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Assessment of basic endoscopic performance using a virtual reality simulator. J Am Coll Surg (2002) 1.86
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int (2011) 1.84
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology (2003) 1.79
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology (2012) 1.71
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol (2007) 1.70
How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol (2006) 1.68
Histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications. J Urol (2003) 1.68
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology (2009) 1.61
Management of ureteral calculi: a cost comparison and decision making analysis. J Urol (2002) 1.57
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol (2008) 1.55
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int (2007) 1.50
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology (2009) 1.45
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol (2011) 1.44
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol (2002) 1.43
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier? Urology (2008) 1.40
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study. Int J Urol (2012) 1.40
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int (2014) 1.39
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res (2008) 1.39
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate (2004) 1.38
Methods of developing UWIN, the modified American Urological Association symptom score. J Urol (2011) 1.37
Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases. Arch Pathol Lab Med (2008) 1.33
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int (2011) 1.31
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol (2012) 1.30
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate (2007) 1.29
A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int (2005) 1.28
Idiopathic scrotal elephantiasis. Urology (2005) 1.28
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26
Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int (2011) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology (2007) 1.24
Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med (2007) 1.23
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer (2008) 1.21
High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol (2005) 1.20